Angel Investing in DeepTech: Milestones Before Revenue
The decision this article answers
A deeptech company may need several years to prove its science, manufacture a working system and sell to its first buyer. Evaluating it like a consumer app produces false conclusions. The investment question is whether the proposed round buys a meaningful reduction in technical or commercial uncertainty. Revenue matters eventually, but early evidence may take the form of repeatable test results, independent validation, prototype reliability, regulatory readiness or signed development agreements. Calling a technology disruptive is not a substitute for showing that the underlying performance can be reproduced.
How the structure actually works
Separate scientific feasibility, engineering feasibility, manufacturability and customer adoption. A laboratory demonstration may establish a physical effect without proving the startup can produce it at acceptable cost. Ask for test protocols, sample counts, failure results, third-party observations, bill of materials and intellectual-property ownership. A technology-readiness label is useful only when the evidence behind the label is visible. Identify the highest-risk dependency: specialised equipment, export-controlled parts, a regulator, university IP or access to an expensive testing facility.
Worked example and practical comparison
Consider a ₹12 crore development round for a specialised sensor. Management proposes ₹5 crore for engineering, ₹3 crore for test facilities, ₹2 crore for certifications and ₹2 crore for working capital. The investor should not ask only whether the total budget is affordable. Ask what happens after ₹5 crore if the sensor cannot achieve the target error rate, who independently verifies the result, and whether the remaining funding can be redirected. In a milestone-based plan, the next financing decision becomes linked to evidence rather than calendar dates.
Where the investment case can fail
Customer validation is complicated in research-heavy sectors. Letters of interest may reflect technical curiosity rather than procurement authority. Separate funded pilot contracts, unpaid collaborations, memoranda of understanding and purchase orders. If a large institution is testing the product, determine whether it has a pathway to deployment and what conditions trigger payment. A specialist technical adviser should challenge assumptions with enough independence to disagree with the founders. Investors should avoid treating expert endorsements as guarantees of commercial success.
What investors frequently overlook
Dilution risk can be high when long development cycles require successive rounds before large revenue. Model the shares a seed investor may own after a priced Series A and one further financing, including option pools and any liquidation preferences. Compare the founding team's capital need with potential non-dilutive support, but do not assume grants will arrive. A large technical moat can coexist with weak economics if the product is expensive to manufacture, customers are scarce or procurement times are exceptionally long.
A decision rule before investing
Proceed only when the next technical milestone is specific, measurable and financeable, and when a credible customer would care if the company reaches it. Document the milestone, the evidence acceptable to the board, spending until that milestone and how many months remain for course correction. A good deeptech investment case acknowledges what has not been proved. The upside derives from reducing uncertainty step by step, not from projecting a valuation multiple on an untested product.
Additional decision test: evidence and price discipline
Tie deeptech capital to progressively harder evidence. A laboratory result may justify another phase of engineering; engineering repeatability may justify pilot manufacture; pilot manufacture may justify qualification and then sales expansion. Each phase should have a budget, objective pass/fail criteria and a realistic contingency when an experiment fails. Check whether the venture has enough time to obtain third-party test appointments before cash runs low. If a patent or university licence is central, identify limits on commercial use and who pays the costs of maintaining protection. A large projected market matters only if the device or process can be produced and maintained at a cost buyers will accept. A sophisticated slide showing a technology-readiness label is less persuasive than a dated test report listing both successful and unsuccessful attempts.
Documents and questions to verify
Use the following four questions when interviewing the manager, founders or transaction counsel. For every answer, record a source document or independent confirmation, the document date and any unresolved exceptions. A verbal assurance should remain an open item until the underlying evidence is reviewed.
Review reproducible technical results and independent test methodology.
Map technical milestones to cash budgets, equipment and specialist hires.
Validate IP licences, assignment rights and facility access.
Confirm whether target buyers have procurement and deployment budgets.
Red flags that justify pausing the decision
The prototype works only under undocumented conditions.
The founder conflates unpaid research trials with purchase commitments.
The budget funds development but omits certification and scale-up.
A warning sign is not automatic proof of wrongdoing. It is a reason to ask for evidence, model the downside more conservatively or decline the deal when a material issue cannot be resolved.
Sources and publication notes
Verified internal: Rupeia Journal, topic index · Checked 4 Nov 2026
External source: IP India: Patents Act resources and current legislation (Site checked 4 Nov 2026) · Open source
External source: Patents Act 1970, section 68 (assignments) (Statute page checked 4 Nov 2026) · Open source
External source: Startup India: DPIIT recognition and tax exemption (Live guidance checked 4 Nov 2026) · Open source
Verification date: 4 November 2026. Regulatory rules, taxation and transaction documents require current case-specific review. Worked examples are educational and are not forecasts of actual investments.
More in Angel Investing
Continue with related articles in the same private-markets topic cluster.
Related questions
Does a deeptech startup need revenue at seed stage?
Not necessarily; it needs credible evidence of technical progress and a path to paying customers.
Can patents substitute for testing?
No. Patents and technical performance address different risks.
What is the key financing question?
Whether this round reaches a value-changing milestone before cash runs out.
Need personalized advice?
Schedule a conversation about your private market allocation goals.
Request an advisory call